Adequação de protocolos de classificação de risco para COVID-19 às orientações da OMS: uma proposta de instrumento

Objective: This article proposes to create an instrument to analyze the adequacy of risk classification protocols for COVID-19 to the guidelines of the World Health Organization (WHO) and analyzes the protocol used by Santa Catarina. Method: The descriptive research was composed of three parts: 1) extraction of information regarding risk analysis and COVID-19 from WHO documents; 2) elaboration of an instrument to analyze the adequacy of risk classification protocols for COVID-19 to the WHO guidelines; 3) application of the instrument to the protocol used in the state of Santa Catarina. Results: Five WHO documents were reviewed. The built instrument included five dimensions: risk assessment itself, exposure assessment, context assessment, risk characterization and reliability. Partial information regarding the risk assessment itself and reliability was found in the Santa Catarina government protocol. No information was found regarding the other dimensions. Discussion: The mismatch between the matrix used by the state of Santa Catarina and the WHO risk analysis guidelines is huge. Thus, without an adequate analysis of these factors, the entire strategy for implementing actions can be compromised, exposing the population of the state to risk.Objetivo: Este artigo propõe criar um instrumento para analisar a adequação de protocolos de classificação de risco para COVID-19 às orientações da Organização Mundial de Saúde (OMS) e analisa o protocolo utilizado por Santa Catarina. Método: A pesquisa descritiva foi composta de três partes: 1) extração de informações concernentes à análise de risco e à COVID-19 dos documentos da OMS; 2) elaboração de instrumento para análise da adequação de protocolos de classificação de risco para COVID-19 às orientações da OMS; 3) aplicação do instrumento ao protocolo utilizado no estado de Santa Catarina. Resultados: Cinco documentos da OMS foram revistos. O instrumento construído contemplou cinco dimensões: avaliação do risco em si, avaliação da exposição, avaliação do contexto, caracterização do risco e confiabilidade. Informações parciais com relação à avaliação do risco em si e à confiabilidade foram encontradas no protocolo do governo catarinense. Não foram encontradas informações com relação às demais dimensões. Discussão: O desencontro entre a matriz utilizada pelo estado de Santa Catarina e as orientações para análise de risco da OMS são grandes. Assim, sem uma análise adequada desses fatores toda a estratégia de implementação de ações pode ser comprometida, expondo a população do estado a risco

La pandemia de COVID-19 en Brasil : serie de proyecciones del Institute for Health Metrics and Evaluation y la evolución observada, desde mayo hasta agosto, 2020

Objetivo: Descrever as projeções do Institute for Health Metrics and Evaluation (IHME) para a COVID-19 no Brasil e seus estados, apresentar sua acurácia e discutir suas implicações. Métodos: As previsões do IHME de maio a agosto de 2020, para o Brasil e alguns estados, foram comparadas ao número de mortes cumulativas observadas. Resultados: A projeção prevê 182.809 mortes causadas pela pandemia até 1º de dezembro de 2020 no Brasil. O aumento no uso de máscara poderia poupar ~17 mil óbitos. O erro médio no número acumulado de óbitos em duas, quatro e seis semanas das projeções foi de 13%, 18% e 22% respectivamente. Conclusão: Projeções de curto e médio prazo dispõem dados importantes e acurácia suficiente para informar os gestores de saúde, autoridades eleitas e sociedade geral. Após trajeto difícil até agosto, a pandemia, conforme as projeções, terá declínio sustentado, embora demorado, causando em média 400 óbitos/dia no início de dezembro.Objective: To describe the Institute for Health Metrics and Evaluation (IHME) projections for the COVID-19 pandemic in Brazil and the Brazilian states, present their accuracy and discuss their implications. Methods: The IHME projections from May to August 2020 for Brazil and selected states were compared with the ensuing reported number of cumulative deaths. Results: The pandemic is projected to cause 182,809 deaths by December 1, 2020 in Brazil. An increase in mask use could reduce the projected death toll by ~17,000. The mean error in the cumulative number of deaths at 2, 4 and 6 weeks after the projections were made was 13%, 18% and 22%, respectively. Conclusion: Short and medium-term projections provide important and sufficiently accurate data to inform health managers, elected officials, and society at large. After following an arduous course up until August, the pandemic is projected to decline steadily although slowly, with ~400 deaths/day still occurring in early December.Objetivo: Describir las proyecciones del Institute for Health Metrics and Evaluation para COVID-19 en Brasil y sus estados, presentar su precisión y discutir sus implicaciones. Métodos: Las previsiones del IHME de mayo a agosto de 2020 para Brasil y algunos estados, se compararon con las muertes acumuladas observadas. Resultados: La proyección prevé 182.809 muertes por la pandemia hasta el 1º de diciembre de 2020 en Brasil. Un aumento en el uso de mascarillas podría evitar ~17.000 muertes. El error medio en el número acumulado de muertes en 2, 4 y 6 semanas de las proyecciones fue de 13%, 18% y 22%. Conclusión: Las proyecciones de corto y medio plazo proporcionan datos importantes y con suficiente precisión para informar a los administradores de salud, autoridades electas y a la sociedad. Después de un camino difícil hasta agosto, la pandemia, según las proyecciones, tendrá una disminución sostenida, pero lenta, y seguirá causando alrededor de 400 muertes/día a principios de diciembre

Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

As mortality rates decline, life expectancy increases, and populations age, non-fatal outcomes of diseases and injuries are becoming a larger component of the global burden of disease. The Global Burden of Diseases, Injuries, and Risk Factors Study 2016 (GBD 2016) provides a comprehensive assessment of prevalence, incidence, and years lived with disability (YLDs) for 328 causes in 195 countries and territories from 1990 to 2016

Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

BACKGROUND: Measurement of changes in health across locations is useful to compare and contrast changing epidemiological patterns against health system performance and identify specific needs for resource allocation in research, policy development, and programme decision making. Using the Global Burden of Diseases, Injuries, and Risk Factors Study 2016, we drew from two widely used summary measures to monitor such changes in population health: disability-adjusted life-years (DALYs) and healthy life expectancy (HALE). We used these measures to track trends and benchmark progress compared with expected trends on the basis of the Socio-demographic Index (SDI). METHODS: We used results from the Global Burden of Diseases, Injuries, and Risk Factors Study 2016 for all-cause mortality, cause-specific mortality, and non-fatal disease burden to derive HALE and DALYs by sex for 195 countries and territories from 1990 to 2016. We calculated DALYs by summing years of life lost and years of life lived with disability for each location, age group, sex, and year. We estimated HALE using age-specific death rates and years of life lived with disability per capita. We explored how DALYs and HALE differed from expected trends when compared with the SDI: the geometric mean of income per person, educational attainment in the population older than age 15 years, and total fertility rate. FINDINGS: The highest globally observed HALE at birth for both women and men was in Singapore, at 75·2 years (95% uncertainty interval 71·9-78·6) for females and 72·0 years (68·8-75·1) for males. The lowest for females was in the Central African Republic (45·6 years [42·0-49·5]) and for males was in Lesotho (41·5 years [39·0-44·0]). From 1990 to 2016, global HALE increased by an average of 6·24 years (5·97-6·48) for both sexes combined. Global HALE increased by 6·04 years (5·74-6·27) for males and 6·49 years (6·08-6·77) for females, whereas HALE at age 65 years increased by 1·78 years (1·61-1·93) for males and 1·96 years (1·69-2·13) for females. Total global DALYs remained largely unchanged from 1990 to 2016 (-2·3% [-5·9 to 0·9]), with decreases in communicable, maternal, neonatal, and nutritional (CMNN) disease DALYs offset by increased DALYs due to non-communicable diseases (NCDs). The exemplars, calculated as the five lowest ratios of observed to expected age-standardised DALY rates in 2016, were Nicaragua, Costa Rica, the Maldives, Peru, and Israel. The leading three causes of DALYs globally were ischaemic heart disease, cerebrovascular disease, and lower respiratory infections, comprising 16·1% of all DALYs. Total DALYs and age-standardised DALY rates due to most CMNN causes decreased from 1990 to 2016. Conversely, the total DALY burden rose for most NCDs; however, age-standardised DALY rates due to NCDs declined globally. INTERPRETATION: At a global level, DALYs and HALE continue to show improvements. At the same time, we observe that many populations are facing growing functional health loss. Rising SDI was associated with increases in cumulative years of life lived with disability and decreases in CMNN DALYs offset by increased NCD DALYs. Relative compression of morbidity highlights the importance of continued health interventions, which has changed in most locations in pace with the gross domestic product per person, education, and family planning. The analysis of DALYs and HALE and their relationship to SDI represents a robust framework with which to benchmark location-specific health performance. Country-specific drivers of disease burden, particularly for causes with higher-than-expected DALYs, should inform health policies, health system improvement initiatives, targeted prevention efforts, and development assistance for health, including financial and research investments for all countries, regardless of their level of sociodemographic development. The presence of countries that substantially outperform others suggests the need for increased scrutiny for proven examples of best practices, which can help to extend gains, whereas the presence of underperforming countries suggests the need for devotion of extra attention to health systems that need more robust support. FUNDING: Bill & Melinda Gates Foundation

Rationale, study design, and analysis plan of the Alveolar Recruitment for ARDS Trial (ART): Study protocol for a randomized controlled trial

Background: Acute respiratory distress syndrome (ARDS) is associated with high in-hospital mortality. Alveolar recruitment followed by ventilation at optimal titrated PEEP may reduce ventilator-induced lung injury and improve oxygenation in patients with ARDS, but the effects on mortality and other clinical outcomes remain unknown. This article reports the rationale, study design, and analysis plan of the Alveolar Recruitment for ARDS Trial (ART). Methods/Design: ART is a pragmatic, multicenter, randomized (concealed), controlled trial, which aims to determine if maximum stepwise alveolar recruitment associated with PEEP titration is able to increase 28-day survival in patients with ARDS compared to conventional treatment (ARDSNet strategy). We will enroll adult patients with ARDS of less than 72 h duration. The intervention group will receive an alveolar recruitment maneuver, with stepwise increases of PEEP achieving 45 cmH(2)O and peak pressure of 60 cmH2O, followed by ventilation with optimal PEEP titrated according to the static compliance of the respiratory system. In the control group, mechanical ventilation will follow a conventional protocol (ARDSNet). In both groups, we will use controlled volume mode with low tidal volumes (4 to 6 mL/kg of predicted body weight) and targeting plateau pressure <= 30 cmH2O. The primary outcome is 28-day survival, and the secondary outcomes are: length of ICU stay; length of hospital stay; pneumothorax requiring chest tube during first 7 days; barotrauma during first 7 days; mechanical ventilation-free days from days 1 to 28; ICU, in-hospital, and 6-month survival. ART is an event-guided trial planned to last until 520 events (deaths within 28 days) are observed. These events allow detection of a hazard ratio of 0.75, with 90% power and two-tailed type I error of 5%. All analysis will follow the intention-to-treat principle. Discussion: If the ART strategy with maximum recruitment and PEEP titration improves 28-day survival, this will represent a notable advance to the care of ARDS patients. Conversely, if the ART strategy is similar or inferior to the current evidence-based strategy (ARDSNet), this should also change current practice as many institutions routinely employ recruitment maneuvers and set PEEP levels according to some titration method.Hospital do Coracao (HCor) as part of the Program 'Hospitais de Excelencia a Servico do SUS (PROADI-SUS)'Brazilian Ministry of Healt

Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015 : a novel analysis from the Global Burden of Disease Study 2015

Background National levels of personal health-care access and quality can be approximated by measuring mortality rates from causes that should not be fatal in the presence of effective medical care (ie, amenable mortality). Previous analyses of mortality amenable to health care only focused on high-income countries and faced several methodological challenges. In the present analysis, we use the highly standardised cause of death and risk factor estimates generated through the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) to improve and expand the quantification of personal health-care access and quality for 195 countries and territories from 1990 to 2015. Methods We mapped the most widely used list of causes amenable to personal health care developed by Nolte and McKee to 32 GBD causes. We accounted for variations in cause of death certification and misclassifications through the extensive data standardisation processes and redistribution algorithms developed for GBD. To isolate the effects of personal health-care access and quality, we risk-standardised cause-specific mortality rates for each geography-year by removing the joint effects of local environmental and behavioural risks, and adding back the global levels of risk exposure as estimated for GBD 2015. We employed principal component analysis to create a single, interpretable summary measure-the Healthcare Quality and Access (HAQ) Index-on a scale of 0 to 100. The HAQ Index showed strong convergence validity as compared with other health-system indicators, including health expenditure per capita (r= 0.88), an index of 11 universal health coverage interventions (r= 0.83), and human resources for health per 1000 (r= 0.77). We used free disposal hull analysis with bootstrapping to produce a frontier based on the relationship between the HAQ Index and the Socio-demographic Index (SDI), a measure of overall development consisting of income per capita, average years of education, and total fertility rates. This frontier allowed us to better quantify the maximum levels of personal health-care access and quality achieved across the development spectrum, and pinpoint geographies where gaps between observed and potential levels have narrowed or widened over time. Findings Between 1990 and 2015, nearly all countries and territories saw their HAQ Index values improve; nonetheless, the difference between the highest and lowest observed HAQ Index was larger in 2015 than in 1990, ranging from 28.6 to 94.6. Of 195 geographies, 167 had statistically significant increases in HAQ Index levels since 1990, with South Korea, Turkey, Peru, China, and the Maldives recording among the largest gains by 2015. Performance on the HAQ Index and individual causes showed distinct patterns by region and level of development, yet substantial heterogeneities emerged for several causes, including cancers in highest-SDI countries; chronic kidney disease, diabetes, diarrhoeal diseases, and lower respiratory infections among middle-SDI countries; and measles and tetanus among lowest-SDI countries. While the global HAQ Index average rose from 40.7 (95% uncertainty interval, 39.0-42.8) in 1990 to 53.7 (52.2-55.4) in 2015, far less progress occurred in narrowing the gap between observed HAQ Index values and maximum levels achieved; at the global level, the difference between the observed and frontier HAQ Index only decreased from 21.2 in 1990 to 20.1 in 2015. If every country and territory had achieved the highest observed HAQ Index by their corresponding level of SDI, the global average would have been 73.8 in 2015. Several countries, particularly in eastern and western sub-Saharan Africa, reached HAQ Index values similar to or beyond their development levels, whereas others, namely in southern sub-Saharan Africa, the Middle East, and south Asia, lagged behind what geographies of similar development attained between 1990 and 2015. Interpretation This novel extension of the GBD Study shows the untapped potential for personal health-care access and quality improvement across the development spectrum. Amid substantive advances in personal health care at the national level, heterogeneous patterns for individual causes in given countries or territories suggest that few places have consistently achieved optimal health-care access and quality across health-system functions and therapeutic areas. This is especially evident in middle-SDI countries, many of which have recently undergone or are currently experiencing epidemiological transitions. The HAQ Index, if paired with other measures of health-systemcharacteristics such as intervention coverage, could provide a robust avenue for tracking progress on universal health coverage and identifying local priorities for strengthening personal health-care quality and access throughout the world. Copyright (C) The Author(s). Published by Elsevier Ltd.Peer reviewe

A study of global environmental burden of diarrhea in children in Brazil: attributable to inadequate sanitation

Submitted by Gilvan Almeida ([email protected]) on 2016-08-10T18:28:40Z No. of bitstreams: 2 604.pdf: 701934 bytes, checksum: 68e1c20a73440aaea3cbe89b6b309a3a (MD5) license.txt: 1748 bytes, checksum: 8a4605be74aa9ea9d79846c1fba20a33 (MD5)Approved for entry into archive by Maria Arruda ([email protected]) on 2018-02-01T13:35:30Z (GMT) No. of bitstreams: 2 604.pdf: 701934 bytes, checksum: 68e1c20a73440aaea3cbe89b6b309a3a (MD5) license.txt: 1748 bytes, checksum: 8a4605be74aa9ea9d79846c1fba20a33 (MD5)Made available in DSpace on 2018-02-01T13:35:30Z (GMT). No. of bitstreams: 2 604.pdf: 701934 bytes, checksum: 68e1c20a73440aaea3cbe89b6b309a3a (MD5) license.txt: 1748 bytes, checksum: 8a4605be74aa9ea9d79846c1fba20a33 (MD5) Previous issue date: 2013Fundação Oswaldo Cruz. Escola Nacional de Saúde Pública Sergio Arouca. Rio de Janeiro, RJ, Brasil.Introdução: A Carga Global de Doença é a métrica adotada pela Organização Mundial de Saúde e por diversos países como suporte para a tomada de decisão em saúde pública baseada em evidências. O estudo dos fatores de risco ambientais e seus impactos na saúde da população mundial integram esta metodologia, em particular, o fator de risco saneamento, água e higiene inseguros devido ao seu impacto na saúde da população mundial, principalmente em países em desenvolvimento, como o Brasil.Objetivo: Estimar a Carga Global da Diarreia em crianças menores de 05 anos atribuível ao fator de risco saneamento, água e higiene inseguros no Brasil e suas macrorregiões para o ano de 1998. Metodologia: A Carga Global da Diarreia em crianças menores de 05 anos no Brasil e macrorregiões foi estimada a partir da Fração Populacional Atribuível para três cenários distintos de exposição ao fator de risco saneamento, qualidade da água e higiene inseguros (I acesso à rede geral de esgoto, mas ausência de acesso à rede de abastecimento de água; II acesso à rede geral de abastecimento de água mas ausência do acesso à rede geral de esgoto e III ausência de acesso à rede geral de esgoto e à rede geral de abastecimento de água). Os dados de prevalência e risco relativo para estimação da FPA foram obtidos, respectivamente, através do Censo 2000 (IBGE, 2000) e publicação identificada através da realização de uma revisão sistemática. (...) Discussão: Os resultados obtidos permitiram identificar lacunas no conhecimento brasileiro relacionadas à ausência de estudos longitudinais e dados de morbidade associados à diarreia. A comparação da estimação brasileira com estudos semelhantes realizados em outros países está comprometida em virtude da diferença entre os pressupostos metodológicos assumidos em todos os estudos, alterando, deste modo, os resultados obtidos.A estimação da Carga Ambiental da Diarreia no Brasil permite avaliar o alcance das metas assumidas pelo Brasil nos Objetivos de Desenvolvimento do Milênio, especificamente os Objetivos IV e VII que se referem à redução da mortalidade infantil e à promoção da sustentabilidade. Conclusão: A Carga Global da Diarreia no Brasil foi de 15,2% em 1998, principalmente devido a ausência de acesso à rede geral de esgoto no Brasil e nas macrorregiões. Os resultados obtidos indicam que a oferta de estruturas sanitárias no Brasil ainda ocorre de maneira distinta, com maior carência nas regiões com maiores áreas rurais (Norte e Nordeste) e, consequente, aumento na Carga Global da Diarreia

Doenças sensíveis ao clima no Brasil e no mundo: revisão sistemática

Objetivos. Fazer um levantamento da literatura existente acerca das doenças sensíveis ao clima (DSC) e dos impactos das alterações climáticas sobre a saúde. Método. A revisão sistemática foi conduzida conforme a metodologia PRISMA. As buscas foram realizadas nas bases LILACS, PubMed, Scopus e SciELO em julho de 2017, sem restrição temporal. Em todas as bases utilizou-se a seguinte estratégia de busca: (climate) AND (disease) AND (sensitive). As buscas foram realizadas em inglês, espanhol e português. Resultados. Foram selecionadas 106 publicações. As doenças mais estudadas foram dengue, malária e doenças respiratórias e cardiovasculares. As variáveis climáticas mais estudadas foram temperatura e precipitação. Os estudos mostraram uma relação entre a incidência de determinadas de doenças, principalmente doenças cardiovasculares e respiratórias, dengue, malária e arboviroses, e as condições climáticas em diferentes regiões do mundo. Essa relação foi analisada considerando tanto dados pretéritos de incidência de doenças e variáveis climáticas como pela projeção futura de incidência de doenças de acordo com variações previstas do clima. Identificou-se um número maior de estudos realizados por autores oriundos de países desenvolvidos. Os locais estudados com maior frequência foram China, Estados Unidos, Austrália e Brasil. Conclusões. Apesar do aumento no número de artigos publicados sobre o tema, é preciso enfocar um número maior de variáveis climáticas e ambientais e expandir os estudos para outras regiões do globo

Duration of post-vaccination immunity against yellow fever in adults

Submitted by Nuzia Santos ([email protected]) on 2015-06-22T17:37:43Z No. of bitstreams: 1 2014_152.pdf: 756403 bytes, checksum: c18d98237e29e19e785cf895a2a68ddc (MD5)Approved for entry into archive by Nuzia Santos ([email protected]) on 2015-06-22T17:37:52Z (GMT) No. of bitstreams: 1 2014_152.pdf: 756403 bytes, checksum: c18d98237e29e19e785cf895a2a68ddc (MD5)Approved for entry into archive by Nuzia Santos ([email protected]) on 2015-06-22T17:58:36Z (GMT) No. of bitstreams: 1 2014_152.pdf: 756403 bytes, checksum: c18d98237e29e19e785cf895a2a68ddc (MD5)Made available in DSpace on 2015-06-22T17:58:36Z (GMT). No. of bitstreams: 1 2014_152.pdf: 756403 bytes, checksum: c18d98237e29e19e785cf895a2a68ddc (MD5) Previous issue date: 2014Fundação Oswaldo Cruz. Brasilia, DF, BrasilFundação Oswaldo Cruz. Escola Nacional de Saúde Pública. Rio de Janeiro, RJ, BrazilFundação Oswaldo Cruz. Centro de Pesquisa Rene Rachou. Laboratório de Biomarcadores Belo Horizonte, MG, BrasilFundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicosde Bio-Manguinhos. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos de Bio-Manguinhos. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos de Bio-Manguinhos. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos de Bio-Manguinhos. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos de Bio-Manguinhos. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos de Bio-Manguinhos. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos de Bio-Manguinhos. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos de Bio-Manguinhos. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos de Bio-Manguinhos. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos de Bio-Manguinhos. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos de Bio-Manguinhos. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos de Bio-Manguinhos. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos de Bio-Manguinhos. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos de Bio-Manguinhos. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos de Bio-Manguinhos. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos de Bio-Manguinhos. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos de Bio-Manguinhos. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos de Bio-Manguinhos. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos de Bio-Manguinhos. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos de Bio-Manguinhos. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos de Bio-Manguinhos. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos de Bio-Manguinhos. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos de Bio-Manguinhos. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos de Bio-Manguinhos. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos de Bio-Manguinhos. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos de Bio-Manguinhos. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos de Bio-Manguinhos. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos de Bio-Manguinhos. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos de Bio-Manguinhos. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Centro de Pesquisa Rene Rachou. Laboratório de Biomarcadores. Belo Horizonte, MG, BrasilFundação Oswaldo Cruz. Centro de Pesquisa Rene Rachou. Laboratório de Biomarcadores. Belo Horizonte, MG, BrasilFundação Oswaldo Cruz. Centro de Pesquisa Rene Rachou. Laboratório de Imunopatologia .Belo Horizonte, MG, BrasilFundação Oswaldo Cruz. Centro de Pesquisa Rene Rachou. Laboratório de Esquistossomose. Belo Horizonte, MG, BrasilFundação Oswaldo Cruz. Centro de Pesquisa Rene Rachou. Laboratório de Biomarcadores. Belo Horizonte, MG, BrasilFundação Oswaldo Cruz. Centro de Pesquisa Rene Rachou. Laboratório de Biomarcadores. Belo Horizonte, MG, BrasilFood and Drug Administration Center for Biologics Evaluation and Research. Bethesda, USA.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratorio de Fla-vivirus. Rio de JaneiroFundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratorio de Fla-vivirus. Rio de JaneiroFundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratorio de Fla-vivirus. Rio de JaneiroInstituto de Biologia do Exército. Rio de Janeiro, RJ, BrasilInstituto de Biologia do Exército. Rio de Janeiro, RJ, BrasilInstituto de Biologia do Exército. Rio de Janeiro, RJ, BrasilInstituto de Biologia do Exército. Rio de Janeiro, RJ, BrasilInstituto de Biologia do Exército. Rio de Janeiro, RJ, BrasilInstituto de Biologia do Exército. Rio de Janeiro, RJ, BrasilMinas Gerais. Secretaria Estadual de Saude. Belo Horizonte, MG, BrasilMinas Gerais. Secretaria Estadual de Saude. Belo Horizonte, MG, BrasilMinas Gerais. Secretaria Estadual de Saude. Belo Horizonte, MG, BrasilMinas Gerais. Secretaria Estadual de Saude. Belo Horizonte, MG, BrasilUniversidade Federal de Alfenas. Alfenas, MG, BrasilUniversidade de Brasília. Faculdade de Medicina. Brasilia, DF, BrasilFundação Oswaldo Cruz. Instituto Evandro Chagas. Ananindeua, PA, BrasilINTRODUCTION: Available scientific evidence to recommend or to advise against booster doses of yellow fever vaccine (YFV) is inconclusive. A study to estimate the seropositivity rate and geometric mean titres (GMT) of adults with varied times of vaccination was aimed to provide elements to revise the need and the timing of revaccination. METHODS: Adults from the cities of Rio de Janeiro and Alfenas located in non-endemic areas in the Southeast of Brazil, who had one dose of YFV, were tested for YF neutralising antibodies and dengue IgG. Time (in years) since vaccination was based on immunisation cards and other reliable records. RESULTS: From 2011 to 2012 we recruited 691 subjects (73% males), aged 18-83 years. Time since vaccination ranged from 30 days to 18 years. Seropositivity rates (95%C.I.) and GMT (International Units/mL; 95%C.I.) decreased with time since vaccination: 93% (88-96%), 8.8 (7.0-10.9) IU/mL for newly vaccinated; 94% (88-97), 3.0 (2.5-3.6) IU/mL after 1-4 years; 83% (74-90), 2.2 (1.7-2.8) IU/mL after 5-9 years; 76% (68-83), 1.7 (1.4-2.0) IU/mL after 10-11 years; and 85% (80-90), 2.1 (1.7-2.5) IU/mL after 12 years or more. YF seropositivity rates were not affected by previous dengue infection. CONCLUSIONS:Eventhough serological correlates of protection for yellow fever are unknown, seronegativity in vaccinated subjects may indicate primary immunisation failure, or waning of immunity to levels below the protection threshold. Immunogenicity of YFV under routine conditions of immunisation services is likely to be lower than in controlled studies. Moreover, infants and toddlers, who comprise the main target group in YF endemic regions, and populations with high HIV infection rates, respond to YFV with lower antibody levels. In those settings one booster dose, preferably sooner than currently recommended, seems to be necessary to ensure longer protection for all vaccinee